Armetheon, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded as renamed to Espero Biopharma, Inc. (2020)
0
Ending by 2030
none
Next term end
When these terms end
Held patents by the year their term ends
2026 · 0 end2027 · 02028 · 02029 · 02030 · 0
Fee deadlines
No maintenance fee falls due on this company's record before Nov 20, 2027.
Recent changes
- 2 terms have ended since Aug 22, 2026
- Aug 31 US 7,629,466 Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders · term ended
- Aug 31 US 7,326,787 Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders · term ended
Patents held now
No patent on this record is in force and held under this name now.
Also on record: 2 patents in force now held by others · 2 lapsed for an unpaid fee · 18 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 no status recorded